Generic Celebrex is coming

Share this article:

Teva and Pfizer have settled their Celebrex spat. Teva said in a statement Thursday that the settlement means generics of the pain med in 50mg, 100mg, 200mg and 400mg doses can hit the marketplace in December.

Last year's $3 billion in Celebrex sales represented a 7% increase in worldwide sales compared to 2012, largely supported by price increases and growth in the US.

Pfizer's fight to protect a 2015 patent extension ended last month when a court ruled a patent invalid.

Morningstar analyst Damien Conover told Reuters at the time he expected generics could cost Pfizer $1 billion in 2014.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions